Citations

Showing 10 of 108152 citations.

IDENTIFICATION AND FURTHER CHARACTERIZATION OF TYPE IIE VON WILLEBRAND DISEASE
Triplett, Douglas A., Muagrave, K, Daniels, Todd M., Bowie, E. J. Walter

Mayo Clinic

Thrombosis and Haemostasis | June 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1644107 Get It

Type IIE von Willebrand disease has previously been identified in a single family with two affected members. We have identified a second family with five affected individuals. The pattern of inheritance is autosomal dominant and the clinical picture is characterized by mild mucocutaneous bleeding. Laboratory results for affected patients: VIII:C ranged from .62 u/ml to 1.0 u/ml, VWD antigen 2.0 u/ml to 4.75 u/ml, and ristocetin cofactor activity 0.04 u/ml to .32 u/ml. Bleeding times, PT and APTT results were within normal ranges.Multimeric analysis of both citrated plasma and platelet lysates utilizing sodium dodecyl sulfate-polyacrylamide electrophoresis was characterized by a decrease of the largest oligomers and the individual multimers were abnormal with a single identifiable band. Plasma samples collected in the presence of a variety of inhibitors had no effect on the multi-meric pattern. Intravenous infusion of DDAVP (.3 ug/kg of body weight) resulted in a slight increase in the highest molecular weight oligomers but no change in the ristocetin cofactor activity or individual multimeric patterns.
Long‐term outcomes of the octogenarian donor liver recipient: The era of the new centurion
Schneider, Sarah , Jaime, Francia Díaz , Mara, Kristin C. , Dierkhising, Ross , Watt, Kymberly D. , Berenguer, Marina , Díaz Jaime, Francia , Mara, Kristin, Berenguer, Marina , Mara, Kristin C , Schneider, Sarah, Heimbach, Julie K.

Mayo Clinic

Clinical Transplantation | June 7, 2019 | Volume: 33 | Issue: 8 | Pages: No page available

10.1111/ctr.13629 | PMID 31173653 Get It

AbstractBackgroundStudies have suggested transplantation using older donor livers results in similar short‐term outcomes as younger donor livers; however, little data exist on long‐term patient/graft outcomes of the octogenarian liver recipient.MethodsRetrospective data were collected from 2 centers, (Valencia, Spain and Rochester, MN, USA) of all recipients of octogenarian donor liver allografts from 2000 to 2011 with follow‐up to 2016. The aim was to compare long‐term patient/graft survival as well as metabolic outcomes of the recipient with the octogenarian liver vs younger than 60 years donor.Results78 recipients of older liver allografts were compared to 78 matched controls. No difference in 10‐year patient mortality was demonstrated (P = 0.074). Octogenarian livers were associated with 3‐fold higher likelihood of graft failure (P = 0.002) but no increase in the risk of post‐LT cardiovascular disease (P = 0.60), hypertension (P = 0.33), vascular complications (P = 0.53), or malignancy (P = 0.14). In multivariate analysis, elder livers remained a significant factor associated with rejection (P = 0.034) with a trend not reaching statistical significance for graft failure (P = 0.052).ConclusionsFor appropriately selected recipients, receiving an octogenarian liver does not clearly influence patient survival but does impact early graft survival with a notable increase in early posttransplant rejection rates and re‐transplantation. Over 1.5 decades, older allografts have not adversely affected metabolic outcomes.
Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers
Pennington, Kelly M. , Yost, Kathleen J. , Escalante, Patricio , Kennedy, Cassie C. , Kennedy, Cassie C , Razonable, Raymund R.

Mayo Clinic

Clinical Transplantation | June 7, 2019 | Volume: 33 | Issue: 7 | Pages: No page available

10.1111/ctr.13630 | PMID 31173402 Get It

AbstractBackgroundAntifungal prophylaxis strategies for lung transplant recipients vary without consensus or standard of care. Our current study aims to identify antifungal prophylaxis practices in the United States.MethodsFrom November 29, 2018, to February 15, 2019, we emailed surveys to medical directors of adult lung transplant centers. An alternate physician representative was approached if continued non‐response after three survey attempts. Descriptive statistics were used to report findings.ResultsForty‐four of 62 (71.0%) eligible centers responded. All Organ Procurement and Transplantation Networks were represented. Only four (9.1%) centers used pre‐transplant prophylaxis for prevention of tracheobronchitis (3 of 4) and invasive fungal disease (4 of 4). Thirty‐nine of forty (97.5%) centers used post‐transplant prophylaxis: 36 (90.0%) universal and 3 (7.5%) pre‐emptive/selective prophylaxis. Most centers used nebulized amphotericin with a systemic agent (26 of 36, 72.2%). Thirty‐two of thirty‐six (88.9%) centers continued universal prophylaxis beyond the hospital setting. Duration of prophylaxis ranged from the post‐transplant hospitalization to lifelong with most centers (25 of 36, 69.4%) discontinuing prophylaxis 6 months or less post‐transplant.ConclusionMost United States' lung transplant centers utilize a universal prophylaxis with nebulized amphotericin and a systemic triazole for 6 months or less post‐transplant. Very few centers use pre‐transplant antifungal prophylaxis.
Ultrasound-Guided Proximal and Distal Suprascapular Nerve Blocks: A Comparative Cadaveric Study
Blasco, Laurent, Tibbo, Meagan E. , Fernandes, Olivier, Minville, Vincent , Lopez, R. , Mansat, Pierre , Ferré, Fabrice , Tibbo, Meagan, Laumonerie, Pierre

Mayo Clinic

Pain Medicine | June 7, 2019 | Volume: 21 | Issue: 6 | Pages: 1240-1247

10.1093/pm/pnz157 | PMID 31369679 Get It

Abstract Objectives The primary aim of our study was to evaluate and compare the accuracy of ultrasound (US)-guided distal suprascapular nerve (dSSN) and proximal SSN (pSSN) blocks. Secondary aims were to compare the phrenic nerve involvement between groups and to describe the anatomical features of the sensory branches of the dSSN. Methods pSSN and dSSN blocks were performed in 14 cadavers (28 shoulders). Ten mL of 0.2% ropivacaine colored with methylene blue was injected under US guidance. Accuracy was determined using SSN staining and the distance between predefined anatomical landmarks and the targeted SSN. The phrenic nerve (PN) was judged to be colored or not. The distribution of the sensory branches that originate from the 14 dSSNs is described. Quantitative data are expressed as median (range). Results The pSSN was dyed more frequently than the dSSN (13 vs 11, P = 0.59). The targeted SSN was close to the suprascapular notch (1.3 [0–5.2] cm) and the origin of the SSN (1.4 [0.2–4.5] cm) for dSSN and pSSN blocks, respectively (P = 0.62). For dSSN blocks, the most frequent injection site was the supraspinous fossa. Three PNs were marked in pSSN blocks, compared with none in dSSN blocks (P = 0.22). Three sensory branches were identified for all 14 dSSNs: the medial subacromial branch, the lateral subacromial branch, and the posterior glenohumeral branch. Conclusions US-guided pSSN and dSSN blocks can be realized with accuracy. A distal approach to the SSN could be an alternative to interscalene brachial plexus block for the management of postoperative pain after shoulder surgery in high–respiratory risk patients.
Barriers to accrual and enrollment in brain tumor trials
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , Leone, José Pablo , Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Bent, Martin J. van den , Weller, Michael , Reardon, David A. , Wen, Patrick Y. , Galanis, Evanthia , Weller, Michael , van den Bent, Martin J , Groot, John de , Armstrong, Terri S. , Chang, Susan Marina , Alexander, Brian M. , Bates, Amanda, Lin, Nancy U. , Mehta, Minesh P. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | June 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noz104 | PMID 31175826 Get It

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Coltro, Giacomo , Finke, Christy M. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew , Jevremović, Dragan , Altman, Jessica K. , Patnaik, Mrinal M. , Lasho, Terra L. , Gangat, Naseema , Tefferi, Ayalew , Patnaik, Mrinal , Jevremovic, Dragan

Mayo Clinic

American Journal of Hematology | June 7, 2019 | Volume: 94 | Issue: 9 | Pages: No page available

10.1002/ajh.25552 | PMID 31173385 Get It

Impacting the Next Generation: Teaching Quality and Patient Safety
Harbell, Monica W. , Donnelly, Melanie J. , Rastogi, Rahul , Simmons, Jeffrey W. , Harbell, Monica W

Mayo Clinic

International Anesthesiology Clinics | June 7, 2019 | Volume: 57 | Issue: 3 | Pages: 146-157

10.1097/aia.0000000000000233 | PMID 31577245 Get It

Pancreatobiliary Versus Head and Neck Manifestations in Immunoglobulin G4–related Disease
Mohapatra, Sonmoon , Sharma, Ayush , Chari, Suresh T. , Chari, Suresh T

Mayo Clinic

Pancreas | June 7, 2019 | Volume: 48 | Issue: 6 | Pages: 799-804

10.1097/mpa.0000000000001332 | PMID 31210660 Get It

Objectives We compared the clinical profiles and organ manifestations of the commonly encountered immunoglobulin G4–related diseases (IgG4-RDs) on either side of the diaphragm: head and neck (HN) versus pancreatobiliary (PB) in IgG4-RD. Methods From the Mayo Clinic, Rochester, database, we identified 53 HN and 88 PB IgG4-RD based on the first affected organ manifestation. Results Compared with HN IgG4-RD, subjects with PB IgG4-RD were likely to be older (median, 64.8 vs 50.2 years; P < 0.0001), male (83% vs 60.4%; P = 0.003), and with a shorter duration of follow-up (24.4 vs 48.7 months; P < 0.0001). In HN versus PB-IgG4-RD orbital, lacrimal gland, submandibular, parotid gland, asthma, and sinusitis manifestations were more common (77% vs 4.5%, 21% vs 0%, 32% vs 8%, 13% vs 0%, 36% vs 9%, and 51% vs 6.8%; P < 0.0001, respectively), whereas lung manifestations were similar (13.2% vs 5.6%; P = 0.12). In contrast, in PB versus HN IgG4-RD, pancreas and biliary were more frequent (98.8% vs 15%, 56.8% vs 3.7%; P < 0.0001), whereas renal lesions were similar (12.5% vs 7.5%; P = 0.36). Conclusion Pancreatobiliary and HN IgG4-RD have distinct clinical profiles. Proximity matters in other organ involvement in IgG4-RD, and organs involved tend to cluster close to each.
Contrast-Enhanced Ultrasound-Guided Interventions—The New Sheriff in Town?
Caserta, Melanie P. , Dahiya, Nirvikar , Tchelepi, Hisham

Mayo Clinic

Ultrasound Quarterly | June 7, 2019 | Volume: 36 | Issue: 2 | Pages: 91-101

10.1097/ruq.0000000000000455 | PMID 32515928 Get It

Abstract Ultrasound (US)–guided intervention is a well-established medical procedure and offers advantages such as real-time guidance, portability, reduced cost, shortened procedure time compared with computed tomography, and lack of ionizing radiation. Ultrasound contrast agents (UCAs) are a useful adjunct to US-guided procedures. The addition of microbubble UCAs during US-guided interventions can assist with biopsy planning and lesion selection, aid in identification of target lesions, and direct the biopsy toward viable tissue. Ultrasound contrast agents have been in use outside of the United States for many years and have been used off label at select institutions across the United States before the Food and Drug Administration approval of Lumason (Bracco Diagnostics) for liver lesion evaluation in April 2016. After Food and Drug Administration approval, the use of UCAs has expanded rapidly, and UCAs are being used for a variety of clinical applications. Ultrasound contrast agents have been shown to be safe, and there is no renal toxicity. In this article, we will discuss the indications and techniques for using contrast-enhanced ultrasound during US-guided interventions, and we will present case examples where contrast-enhanced ultrasound added value.
Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers
Chen, Qin , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Haley, Dana , Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Kraft, Ruth, Rademakers, Rosa , Rosen, Howie, Boxer, Adam L. , Kantarci, Kejal , Lesnick, Timothy, Kantarci, Kejal , Boeve, Bradley F. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Journal of Neuroimaging | June 7, 2019 | Volume: 29 | Issue: 5 | Pages: 624-629

10.1111/jon.12642 | PMID 31173437 Get It

ABSTRACT BACKGROUND AND PURPOSE The objective of this study was to longitudinally investigate the trajectory of change in 1 H MRS measurements in asymptomatic MAPT mutation carriers who became symptomatic during follow‐up, and to determine the time at which the neurochemical alterations accelerated during disease progression. METHODS We identified eight MAPT mutations carriers who transitioned from asymptomatic to symptomatic disease during follow‐up. All participants were longitudinally followed with an average of 7.75 years (range 4‐11 years) and underwent two or more single voxel 1 H MRS examinations from the posterior cingulate voxel, with a total of 60 examinations. The rate of longitudinal change for each metabolite was estimated using linear mixed models. A flex point model was used to estimate the flex time point of the change in slope. RESULTS The decrease in the NAA/mI ratio accelerated 2.09 years prior to symptom onset, and continued to decline. A similar trajectory was observed in the presumed glial marker mI/Cr ratio accelerating 1.86 years prior to symptom onset. CONCLUSIONS Our findings support the potential use of longitudinal 1 H MRS for monitoring the neurodegenerative progression in MAPT mutation carriers starting from the asymptomatic stage.